Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis.
Multiple sclerosis may ultimately be effectively treated using appropriate immunosuppressive regimens. Both cytotoxic drugs and therapeutic apheresis may constitute important therapeutic options. A number of studies are currently underway which will hopefully clarify the exact role of these treatment modalities in patients at different stages of disease.
D000208:Acute Disease; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002469:Cell Separation; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D004676:Myelin Basic Protein / Q000097:blood; D010956:Plasmapheresis; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D004676:Myelin Basic Protein; D003520:Cyclophosphamide; D000324:Adrenocorticotropic Hormone; D001379:Azathioprine; D011241:Prednisone